

Study Number: C11042B-01
Test Type: TOX with Perinatal Exposure
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026
Time Report Requested: 11:00:33
Lab: Battelle

Study Number: C11042B-01
Study Sex: Both
PWG Approval Date: See web page for date of PWG Approval
Version: v1.7.8
Stat Version: 2023.02.27S

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026

Time Report Requested: 11:00:33

Lab: Battelle

F1 Male: PND28 Interim Cohort

	Phase Day	Treatment Groups (ppm)				
		0	30	100	300	1000
Urea Nitrogen (mg/dL)	PND 31 - 37	19.5 ± 0.4 (19)	18.1 ± 0.4 (21) *	18.0 ± 0.3 (21) *	18.0 ± 0.5 (20)	19.4 ± 0.4 (22)
Percent of Control			92.6	92.3	92.3	99.1
Creatinine (mg/dL)	PND 31 - 37	0.31 ± 0.01 (19)	0.31 ± 0.01 (21)	0.31 ± 0.01 (21)	0.31 ± 0.01 (20)	0.30 ± 0.01 (22)
Percent of Control			101.2	99.7	98.2	98.1
Glucose (mg/dL)	PND 31 - 37	130.5 ± 1.9 (19)	128.5 ± 2.2 (21)	138.8 ± 3.0 (21)	134.3 ± 1.7 (20)	133.3 ± 1.7 (22)
Percent of Control			98.4	106.4	102.9	102.1
Sodium (mmol/L)	PND 31 - 37	141.3 ± 0.5 (19) **	141.5 ± 0.3 (21)	141.7 ± 0.4 (21)	142.5 ± 0.2 (20)	142.8 ± 0.4 (22)
Percent of Control			100.1	100.3	100.8	101.0
Potassium (mmol/L)	PND 31 - 37	6.4 ± 0.1 (19) **	6.5 ± 0.1 (21)	6.8 ± 0.1 (21) **	6.8 ± 0.1 (20) **	6.9 ± 0.1 (22) **
Percent of Control			102.2	106.1	106.8	107.8
Chloride (mmol/L)	PND 31 - 37	98.7 ± 0.3 (19) **	99.0 ± 0.2 (21)	99.4 ± 0.3 (21)	99.9 ± 0.2 (20) *	99.6 ± 0.3 (22)
Percent of Control			100.2	100.7	101.2	100.9
Total Protein (g/dL)	PND 31 - 37	5.16 ± 0.03 (19) **	5.21 ± 0.04 (21)	5.24 ± 0.04 (21)	5.25 ± 0.04 (20)	5.32 ± 0.05 (22) *
Percent of Control			101.0	101.5	101.8	103.1
Globulin (g/dL)	PND 31 - 37	0.97 ± 0.02 (19) **	1.04 ± 0.02 (21) *	1.03 ± 0.02 (21) *	1.05 ± 0.02 (20) *	1.09 ± 0.02 (22) **
Percent of Control			107.3	106.8	108.5	112.3
A/G Ratio	PND 31 - 37	4.38 ± 0.10 (19) **	4.06 ± 0.08 (21) **	4.10 ± 0.06 (21) *	4.05 ± 0.09 (20) *	3.95 ± 0.08 (22) **
Percent of Control			92.6	93.7	92.5	90.1
Albumin (g/dL)	PND 31 - 37	4.19 ± 0.03 (19)	4.17 ± 0.03 (21)	4.21 ± 0.03 (21)	4.20 ± 0.03 (20)	4.23 ± 0.03 (22)
Percent of Control			99.5	100.5	100.3	101.0
Cholesterol (mg/dL)	PND 31 - 37	110.1 ± 1.7 (19) **	114.7 ± 1.6 (21) *	118.4 ± 1.8 (21) **	125.7 ± 3.1 (20) **	129.4 ± 3.6 (22) **
Percent of Control			104.2	107.6	114.2	117.6

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026

Time Report Requested: 11:00:33

Lab: Battelle

F1 Male: PND28 Interim Cohort

	Phase Day	Treatment Groups (ppm)				
		0	30	100	300	1000
Triglyceride (mg/dL)	PND 31 - 37	95.5 ± 4.9 (19)	93.7 ± 5.2 (21)	91.7 ± 3.8 (21)	94.4 ± 4.2 (20)	96.7 ± 4.3 (22)
Percent of Control			98.1	96.0	98.8	101.3
Alanine Aminotransferase (IU/L)	PND 31 - 37	41.1 ± 0.8 (19)	40.5 ± 1.4 (21)	40.9 ± 0.6 (21)	42.6 ± 0.9 (20)	40.5 ± 1.1 (22)
Percent of Control			98.4	99.5	103.5	98.5
Alkaline Phosphatase (IU/L)	PND 31 - 37	345.1 ± 10.0 (19)	309.0 ± 9.0 (21)	314.4 ± 9.2 (21)	310.7 ± 10.2 (20)	319.5 ± 9.9 (22)
Percent of Control			89.5	91.1	90.0	92.6
Aspartate Aminotransferase (U/L)	PND 31 - 37	102.35 ± 2.43 (19)	99.67 ± 2.20 (21)	97.40 ± 1.79 (21)	100.95 ± 2.59 (20)	98.95 ± 1.86 (22)
Percent of Control			97.4	95.2	98.6	96.7
Creatine Kinase (IU/L)	PND 31 - 37	691.1 ± 56.7 (19)	652.2 ± 44.6 (21)	603.9 ± 42.0 (21)	618.1 ± 57.9 (20)	622.6 ± 38.6 (22)
Percent of Control			94.4	87.4	89.4	90.1
Lactate Dehydrogenase (U/L)	PND 31 - 37	257.8 ± 10.1 (19)	262.7 ± 19.5 (21)	235.7 ± 14.1 (21)	226.4 ± 15.9 (20)	269.5 ± 19.8 (22)
Percent of Control			101.9	91.4	87.8	104.5
Sorbitol Dehydrogenase (IU/L)	PND 31 - 37	12.6 ± 0.4 (19)	12.3 ± 0.3 (21)	12.2 ± 0.2 (21)	13.1 ± 0.4 (20)	12.4 ± 0.2 (22)
Percent of Control			97.7	96.7	103.8	98.0
Bile salt/acids (umol/L)	PND 31 - 37	76.9 ± 3.1 (19)	69.5 ± 3.0 (21)	76.7 ± 2.3 (21)	71.5 ± 2.8 (20)	78.5 ± 2.1 (22)
Percent of Control			90.4	99.8	93.0	102.1

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026

Time Report Requested: 11:00:33

Lab: Battelle

F1 Male: PND28 Interim Cohort

		Treatment Groups
	Phase Day	3000
Urea Nitrogen (mg/dL)	PND 31 - 37	19.0 ± 0.5 (23)
Percent of Control		97.4
Creatinine (mg/dL)	PND 31 - 37	0.32 ± 0.02 (23)
Percent of Control		102.2
Glucose (mg/dL)	PND 31 - 37	128.9 ± 2.0 (23)
Percent of Control		98.8
Sodium (mmol/L)	PND 31 - 37	142.9 ± 0.4 (23)
Percent of Control		101.1
Potassium (mmol/L)	PND 31 - 37	6.8 ± 0.1 (23) **
Percent of Control		107.1
Chloride (mmol/L)	PND 31 - 37	99.9 ± 0.3 (23) *
Percent of Control		101.2
Total Protein (g/dL)	PND 31 - 37	5.28 ± 0.04 (23)
Percent of Control		102.3
Globulin (g/dL)	PND 31 - 37	1.07 ± 0.02 (23) **
Percent of Control		111.0
A/G Ratio	PND 31 - 37	3.94 ± 0.05 (23) **
Percent of Control		89.9
Albumin (g/dL)	PND 31 - 37	4.20 ± 0.03 (23)
Percent of Control		100.3
Cholesterol (mg/dL)	PND 31 - 37	126.2 ± 2.3 (23) **
Percent of Control		114.6

Study Number: C11042B-01
Test Type: TOX with Perinatal Exposure
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026
Time Report Requested: 11:00:33
Lab: Battelle

F1 Male: PND28 Interim Cohort

		Treatment Groups	
	Phase Day	3000	
Triglyceride (mg/dL)	PND 31 - 37	92.6 ± 3.4	(23)
Percent of Control		96.9	
Alanine Aminotransferase (IU/L)	PND 31 - 37	42.5 ± 0.8	(23)
Percent of Control		103.3	
Alkaline Phosphatase (IU/L)	PND 31 - 37	351.6 ± 10.5	(23)
Percent of Control		101.9	
Aspartate Aminotransferase (U/L)	PND 31 - 37	99.46 ± 3.63	(23)
Percent of Control		97.2	
Creatine Kinase (IU/L)	PND 31 - 37	580.6 ± 43.8	(23)
Percent of Control		84.0	
Lactate Dehydrogenase (U/L)	PND 31 - 37	252.7 ± 11.7	(23)
Percent of Control		98.0	
Sorbitol Dehydrogenase (IU/L)	PND 31 - 37	14.6 ± 0.7	(23) *
Percent of Control		115.5	
Bile salt/acids (umol/L)	PND 31 - 37	76.6 ± 2.9	(23)
Percent of Control		99.6	

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026

Time Report Requested: 11:00:33

Lab: Battelle

F1 Female: PND28 Interim Cohort

	Phase Day	Treatment Groups (ppm)				
		0	30	100	300	1000
Urea Nitrogen (mg/dL)	PND 38 - 44	18.3 ± 0.5 (19) **	17.8 ± 0.6 (18)	18.5 ± 0.4 (22)	19.2 ± 0.4 (21)	19.3 ± 0.5 (22)
Percent of Control			96.9	101.3	104.8	105.2
Creatinine (mg/dL)	PND 38 - 44	0.29 ± 0.01 (19) *	0.33 ± 0.01 (18) **	0.32 ± 0.01 (22) **	0.32 ± 0.01 (21) **	0.32 ± 0.01 (22) **
Percent of Control			115.9	110.8	113.6	113.2
Glucose (mg/dL)	PND 38 - 44	127.6 ± 2.1 (19)	132.1 ± 1.1 (18)	133.8 ± 1.5 (22)	132.0 ± 1.6 (21)	130.4 ± 1.8 (22)
Percent of Control			103.5	104.8	103.4	102.2
Sodium (mmol/L)	PND 38 - 44	140.2 ± 0.3 (19) **	141.6 ± 0.4 (18) *	142.0 ± 0.3 (22) **	141.8 ± 0.4 (21) **	141.8 ± 0.4 (22) **
Percent of Control			100.9	101.3	101.1	101.1
Potassium (mmol/L)	PND 38 - 44	6.7 ± 0.1 (19)	6.8 ± 0.1 (18)	6.6 ± 0.1 (22)	6.6 ± 0.1 (21)	6.7 ± 0.1 (22)
Percent of Control			102.0	99.5	98.4	100.8
Chloride (mmol/L)	PND 38 - 44	98.3 ± 0.3 (19) *	99.5 ± 0.4 (18) *	99.7 ± 0.3 (22) *	99.6 ± 0.4 (21) *	99.0 ± 0.3 (22)
Percent of Control			101.3	101.4	101.4	100.7
Total Protein (g/dL)	PND 38 - 44	5.22 ± 0.03 (19) *	5.33 ± 0.04 (18)	5.28 ± 0.04 (22)	5.25 ± 0.03 (21)	5.38 ± 0.04 (22) *
Percent of Control			102.0	101.1	100.4	103.0
Globulin (g/dL)	PND 38 - 44	0.94 ± 0.03 (19) *	1.00 ± 0.02 (18)	0.98 ± 0.03 (22)	0.98 ± 0.02 (21)	1.03 ± 0.02 (22) *
Percent of Control			105.8	103.4	103.3	108.7
A/G Ratio	PND 38 - 44	4.64 ± 0.15 (19) *	4.38 ± 0.08 (18)	4.48 ± 0.13 (22)	4.42 ± 0.09 (21)	4.29 ± 0.07 (22)
Percent of Control			94.4	96.5	95.2	92.4
Albumin (g/dL)	PND 38 - 44	4.28 ± 0.03 (19)	4.33 ± 0.03 (18)	4.30 ± 0.03 (22)	4.27 ± 0.03 (21)	4.35 ± 0.03 (22)
Percent of Control			101.1	100.5	99.7	101.7
Cholesterol (mg/dL)	PND 38 - 44	123.8 ± 2.0 (19) **	131.0 ± 1.7 (18) *	130.0 ± 2.3 (22)	134.0 ± 2.0 (21) **	138.2 ± 3.2 (22) **
Percent of Control			105.8	105.0	108.2	111.6

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026

Time Report Requested: 11:00:33

Lab: Battelle

F1 Female: PND28 Interim Cohort

	Phase Day	Treatment Groups (ppm)				
		0	30	100	300	1000
Triglyceride (mg/dL)	PND 38 - 44	90.3 ± 8.0 (19) **	83.5 ± 5.3 (18)	84.9 ± 6.2 (22)	92.9 ± 4.2 (21)	96.8 ± 5.2 (22)
Percent of Control			92.5	94.1	103.0	107.2
Alanine Aminotransferase (IU/L)	PND 38 - 44	40.3 ± 1.0 (19)	39.7 ± 1.2 (18)	41.0 ± 1.1 (22)	41.9 ± 0.9 (21)	41.7 ± 0.9 (22)
Percent of Control			98.6	101.7	103.9	103.4
Alkaline Phosphatase (IU/L)	PND 38 - 44	361.1 ± 10.8 (19)	313.5 ± 7.5 (18) **	313.3 ± 8.4 (22) **	319.8 ± 8.5 (21) *	329.5 ± 9.4 (22) *
Percent of Control			86.8	86.8	88.6	91.3
Aspartate Aminotransferase (U/L)	PND 38 - 44	104.19 ± 1.58 (19)	103.33 ± 1.43 (18)	106.75 ± 2.25 (22)	107.48 ± 1.55 (21)	108.48 ± 2.41 (22)
Percent of Control			99.2	102.5	103.2	104.1
Creatine Kinase (IU/L)	PND 38 - 44	590.1 ± 50.0 (19)	596.0 ± 33.7 (18)	663.4 ± 47.6 (22)	690.8 ± 47.8 (21)	651.6 ± 41.2 (22)
Percent of Control			101.0	112.4	117.1	110.4
Lactate Dehydrogenase (U/L)	PND 38 - 44	221.3 ± 13.4 (19)	220.8 ± 13.2 (18)	233.8 ± 12.3 (22)	276.1 ± 21.4 (21)	247.2 ± 20.3 (22)
Percent of Control			99.8	105.6	124.8	111.7
Sorbitol Dehydrogenase (IU/L)	PND 38 - 44	12.1 ± 0.3 (19) **	12.3 ± 0.3 (18)	11.6 ± 0.2 (22)	12.3 ± 0.3 (21)	13.4 ± 0.6 (22)
Percent of Control			101.6	96.1	102.2	110.9
Bile salt/acids (umol/L)	PND 38 - 44	76.5 ± 2.9 (19)	64.8 ± 3.6 (18)	70.7 ± 2.5 (22)	72.3 ± 3.2 (21)	74.0 ± 2.9 (22)
Percent of Control			84.7	92.5	94.5	96.8

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Triphenyl Phosphate (TPHP)

CAS Number: 115-86-6

Date Report Requested: 05/22/2026

Time Report Requested: 11:00:33

Lab: Battelle

F1 Female: PND28 Interim Cohort

		Treatment Groups
	Phase Day	3000
Urea Nitrogen (mg/dL)	PND 38 - 44	20.0 ± 0.4 (22)
Percent of Control		109.2
Creatinine (mg/dL)	PND 38 - 44	0.33 ± 0.01 (22) **
Percent of Control		114.8
Glucose (mg/dL)	PND 38 - 44	127.6 ± 1.9 (22)
Percent of Control		100.0
Sodium (mmol/L)	PND 38 - 44	142.6 ± 0.4 (22) **
Percent of Control		101.7
Potassium (mmol/L)	PND 38 - 44	6.7 ± 0.1 (22)
Percent of Control		100.6
Chloride (mmol/L)	PND 38 - 44	100.2 ± 0.4 (22) **
Percent of Control		102.0
Total Protein (g/dL)	PND 38 - 44	5.33 ± 0.03 (22)
Percent of Control		102.1
Globulin (g/dL)	PND 38 - 44	1.00 ± 0.02 (22)
Percent of Control		106.1
A/G Ratio	PND 38 - 44	4.36 ± 0.08 (22)
Percent of Control		93.9
Albumin (g/dL)	PND 38 - 44	4.33 ± 0.03 (22)
Percent of Control		101.2
Cholesterol (mg/dL)	PND 38 - 44	140.5 ± 2.5 (22) **
Percent of Control		113.5

Study Number: C11042B-01
Test Type: TOX with Perinatal Exposure
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026
Time Report Requested: 11:00:33
Lab: Battelle

F1 Female: PND28 Interim Cohort

		Treatment Groups	
	Phase Day	3000	
Triglyceride (mg/dL)	PND 38 - 44	104.7 ± 8.0	(22)
Percent of Control		116.0	
Alanine Aminotransferase (IU/L)	PND 38 - 44	40.6 ± 1.1	(22)
Percent of Control		100.7	
Alkaline Phosphatase (IU/L)	PND 38 - 44	331.7 ± 11.6	(22) *
Percent of Control		91.9	
Aspartate Aminotransferase (U/L)	PND 38 - 44	106.09 ± 1.74	(22)
Percent of Control		101.8	
Creatine Kinase (IU/L)	PND 38 - 44	720.0 ± 48.3	(22)
Percent of Control		122.0	
Lactate Dehydrogenase (U/L)	PND 38 - 44	262.8 ± 23.7	(22)
Percent of Control		118.7	
Sorbitol Dehydrogenase (IU/L)	PND 38 - 44	14.0 ± 0.9	(22)
Percent of Control		116.1	
Bile salt/acids (umol/L)	PND 38 - 44	71.5 ± 3.4	(22)
Percent of Control		93.5	

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026

Time Report Requested: 11:00:33

Lab: Battelle

F1 Male: Subchronic Cohort

	Phase Day	Treatment Groups (ppm)				
		0	30	100	300	1000
Urea Nitrogen (mg/dL)	PND 127 - 129	16.8 ± 0.7 (10)	17.0 ± 0.8 (10)	18.7 ± 0.7 (10)	16.9 ± 0.5 (9)	17.3 ± 0.7 (10)
Percent of Control			101.2	111.3	100.5	103.0
Creatinine (mg/dL)	PND 127 - 129	0.48 ± 0.02 (10)	0.46 ± 0.02 (10)	0.45 ± 0.02 (10)	0.50 ± 0.00 (9)	0.47 ± 0.02 (10)
Percent of Control			95.8	93.8	104.2	97.9
Glucose (mg/dL)	PND 127 - 129	111.5 ± 3.6 (10)	114.6 ± 5.3 (10)	111.3 ± 4.3 (10)	109.6 ± 2.6 (9)	111.6 ± 2.3 (10)
Percent of Control			102.8	99.8	98.3	100.1
Sodium (mmol/L)	PND 127 - 129	145.5 ± 0.3 (10)	146.2 ± 0.5 (10)	148.0 ± 1.2 (10)	146.3 ± 0.3 (9)	147.0 ± 0.7 (10)
Percent of Control			100.5	101.7	100.6	101.0
Potassium (mmol/L)	PND 127 - 129	6.3 ± 0.1 (10)	6.7 ± 0.1 (10)	6.3 ± 0.1 (10)	6.3 ± 0.1 (9)	6.6 ± 0.1 (10)
Percent of Control			104.9	99.7	100.1	104.7
Chloride (mmol/L)	PND 127 - 129	98.2 ± 0.4 (10)	98.6 ± 0.3 (10)	100.5 ± 1.1 (10)	97.8 ± 0.5 (9)	99.0 ± 0.5 (10)
Percent of Control			100.4	102.3	99.6	100.8
Total Protein (g/dL)	PND 127 - 129	6.96 ± 0.07 (10) **	6.93 ± 0.09 (10)	6.98 ± 0.13 (10)	7.17 ± 0.10 (9)	7.39 ± 0.09 (10) **
Percent of Control			99.6	100.3	103.0	106.2
Globulin (g/dL)	PND 127 - 129	2.45 ± 0.03 (10) *	2.49 ± 0.06 (10)	2.55 ± 0.10 (10)	2.60 ± 0.04 (9)	2.60 ± 0.06 (10)
Percent of Control			101.6	104.1	106.1	106.1
A/G Ratio	PND 127 - 129	1.84 ± 0.03 (10)	1.79 ± 0.05 (10)	1.76 ± 0.07 (10)	1.76 ± 0.03 (9)	1.85 ± 0.05 (10)
Percent of Control			97.2	95.4	95.4	100.4

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026

Time Report Requested: 11:00:33

Lab: Battelle

F1 Male: Subchronic Cohort

	Phase Day	Treatment Groups (ppm)				
		0	30	100	300	1000
Albumin (g/dL)	PND 127 - 129	4.51 ± 0.06 (10) **	4.44 ± 0.06 (10)	4.43 ± 0.06 (10)	4.57 ± 0.07 (9)	4.79 ± 0.05 (10) **
Percent of Control			98.4	98.2	101.3	106.2
Cholesterol (mg/dL)	PND 127 - 129	142.4 ± 2.2 (10) **	148.8 ± 6.4 (10)	153.9 ± 7.8 (10)	169.7 ± 7.4 (9) **	172.3 ± 3.2 (10) **
Percent of Control			104.5	108.1	119.1	121.0
Triglyceride (mg/dL)	PND 127 - 129	115.7 ± 9.7 (10)	118.0 ± 6.2 (10)	135.1 ± 18.3 (10)	147.7 ± 12.2 (9)	124.0 ± 5.9 (10)
Percent of Control			102.0	116.8	127.6	107.2
Alanine Aminotransferase (IU/L)	PND 127 - 129	42.9 ± 1.6 (10)	46.3 ± 1.7 (10)	43.6 ± 1.2 (10)	49.7 ± 2.1 (9)	47.3 ± 1.9 (10)
Percent of Control			107.9	101.6	115.8	110.3
Alkaline Phosphatase (IU/L)	PND 127 - 129	224.2 ± 4.0 (10)	190.6 ± 10.1 (10) *	180.3 ± 18.6 (10)	201.6 ± 12.3 (9)	201.6 ± 8.3 (10)
Percent of Control			85.0	80.4	89.9	89.9
Aspartate Aminotransferase (U/L)	PND 127 - 129	81.70 ± 2.52 (10)	85.33 ± 3.31 (9)	94.20 ± 5.83 (10)	94.67 ± 4.63 (9)	92.60 ± 8.23 (10)
Percent of Control			104.4	115.3	115.9	113.3
Creatine Kinase (IU/L)	PND 127 - 129	358.0 ± 39.8 (10)	447.1 ± 65.9 (9)	956.3 ± 171.9 (10)	842.3 ± 204.4 (9)	726.5 ± 231.4 (10)
Percent of Control			124.9	267.1	235.3	202.9
Lactate Dehydrogenase (U/L)	PND 127 - 129	257.9 ± 24.7 (10)	231.1 ± 18.2 (10)	213.6 ± 17.8 (10)	232.9 ± 26.6 (9)	243.8 ± 46.7 (10)
Percent of Control			89.6	82.8	90.3	94.5
Sorbitol Dehydrogenase (IU/L)	PND 127 - 129	12.0 ± 1.2 (10) *	11.5 ± 1.3 (10)	13.1 ± 1.3 (10)	14.5 ± 0.8 (9)	14.1 ± 1.3 (10)

Study Number: C11042B-01
Test Type: TOX with Perinatal Exposure
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026
Time Report Requested: 11:00:33
Lab: Battelle

F1 Male: Subchronic Cohort

		Treatment Groups (ppm)				
	Phase Day	0	30	100	300	1000
Percent of Control			96.2	109.1	120.8	117.9
Bile salt/acids (umol/L)	PND 127 - 129	41.6 ± 4.4 (10)	30.5 ± 4.6 (10)	22.2 ± 4.5 (10) *	37.6 ± 6.1 (9)	29.1 ± 6.3 (10)
Percent of Control			73.3	53.4	90.3	70.0

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Triphenyl Phosphate (TPHP)

CAS Number: 115-86-6

Date Report Requested: 05/22/2026

Time Report Requested: 11:00:33

Lab: Battelle

F1 Male: Subchronic Cohort

		Treatment Groups	
	Phase Day	3000	
Urea Nitrogen (mg/dL)	PND 127 - 129	18.1 ± 0.8	(10)
Percent of Control		107.7	
Creatinine (mg/dL)	PND 127 - 129	0.48 ± 0.01	(10)
Percent of Control		100.0	
Glucose (mg/dL)	PND 127 - 129	111.7 ± 2.6	(10)
Percent of Control		100.2	
Sodium (mmol/L)	PND 127 - 129	146.9 ± 0.6	(10)
Percent of Control		101.0	
Potassium (mmol/L)	PND 127 - 129	6.4 ± 0.1	(10)
Percent of Control		101.3	
Chloride (mmol/L)	PND 127 - 129	98.0 ± 0.4	(10)
Percent of Control		99.8	
Total Protein (g/dL)	PND 127 - 129	7.50 ± 0.10	(10) **
Percent of Control		107.8	
Globulin (g/dL)	PND 127 - 129	2.62 ± 0.06	(10)
Percent of Control		106.9	
A/G Ratio	PND 127 - 129	1.87 ± 0.05	(10)
Percent of Control		101.5	

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026

Time Report Requested: 11:00:33

Lab: Battelle

F1 Male: Subchronic Cohort

	Phase Day	Treatment Groups	
		3000	
Albumin (g/dL)	PND 127 - 129	4.88 ±	0.07 (10) **
Percent of Control		108.2	
Cholesterol (mg/dL)	PND 127 - 129	208.6 ±	6.7 (10) **
Percent of Control		146.5	
Triglyceride (mg/dL)	PND 127 - 129	120.0 ±	5.5 (10)
Percent of Control		103.7	
Alanine Aminotransferase (IU/L)	PND 127 - 129	48.5 ±	2.6 (10)
Percent of Control		113.1	
Alkaline Phosphatase (IU/L)	PND 127 - 129	202.8 ±	10.5 (10)
Percent of Control		90.5	
Aspartate Aminotransferase (U/L)	PND 127 - 129	88.22 ±	8.56 (9)
Percent of Control		108.0	
Creatine Kinase (IU/L)	PND 127 - 129	975.2 ±	424.7 (9)
Percent of Control		272.4	
Lactate Dehydrogenase (U/L)	PND 127 - 129	277.6 ±	45.1 (10)
Percent of Control		107.6	
Sorbitol Dehydrogenase (IU/L)	PND 127 - 129	14.5 ±	1.2 (10)

Study Number: C11042B-01
Test Type: TOX with Perinatal Exposure
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026
Time Report Requested: 11:00:33
Lab: Battelle

F1 Male: Subchronic Cohort

	Phase Day	Treatment Groups
Percent of Control		3000 120.8
Bile salt/acids (umol/L)	PND 127 - 129	36.7 ± 4.9 (10)
Percent of Control		88.2

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary

Test Compound: Triphenyl Phosphate (TPHP)

CAS Number: 115-86-6

Date Report Requested: 05/22/2026

Time Report Requested: 11:00:33

Lab: Battelle

F1 Female: Subchronic Cohort

	Phase Day	Treatment Groups (ppm)				
		0	30	100	300	1000
Urea Nitrogen (mg/dL)	PND 126	17.7 ± 0.6 (10)	16.4 ± 0.5 (9)	17.3 ± 0.3 (8)	16.4 ± 0.6 (10)	17.6 ± 0.8 (10)
Percent of Control			92.9	97.5	92.7	99.4
Creatinine (mg/dL)	PND 126	0.52 ± 0.01 (10)	0.53 ± 0.02 (9)	0.53 ± 0.02 (8)	0.53 ± 0.02 (10)	0.55 ± 0.02 (10)
Percent of Control			102.6	101.0	101.9	105.8
Glucose (mg/dL)	PND 126	110.7 ± 3.1 (10)	112.6 ± 3.2 (9)	125.1 ± 8.1 (8)	107.6 ± 2.7 (10)	106.1 ± 2.7 (10)
Percent of Control			101.7	113.0	97.2	95.8
Sodium (mmol/L)	PND 126	145.1 ± 0.7 (10)	144.8 ± 0.4 (9)	146.8 ± 0.6 (8)	146.4 ± 0.8 (10)	144.8 ± 0.4 (10)
Percent of Control			99.8	101.1	100.9	99.8
Potassium (mmol/L)	PND 126	6.3 ± 0.1 (10)	6.2 ± 0.1 (9)	5.9 ± 0.2 (8)	6.2 ± 0.1 (10)	6.2 ± 0.1 (10)
Percent of Control			97.9	94.0	99.2	98.9
Chloride (mmol/L)	PND 126	100.0 ± 0.7 (10)	100.4 ± 0.5 (9)	102.4 ± 0.5 (8) *	101.1 ± 0.5 (10)	100.3 ± 0.3 (10)
Percent of Control			100.4	102.4	101.1	100.3
Total Protein (g/dL)	PND 126	7.28 ± 0.14 (10)	7.23 ± 0.10 (9)	7.31 ± 0.20 (8)	7.32 ± 0.13 (10)	7.42 ± 0.09 (10)
Percent of Control			99.4	100.4	100.5	101.9
Globulin (g/dL)	PND 126	2.04 ± 0.05 (10)	2.03 ± 0.06 (9)	2.05 ± 0.07 (8)	2.07 ± 0.08 (10)	2.15 ± 0.03 (10)
Percent of Control			99.7	100.5	101.5	105.4
A/G Ratio	PND 126	2.58 ± 0.07 (10)	2.58 ± 0.11 (9)	2.58 ± 0.11 (8)	2.57 ± 0.10 (10)	2.46 ± 0.05 (10)
Percent of Control			100.0	100.2	99.6	95.3
Albumin (g/dL)	PND 126	5.24 ± 0.12 (10)	5.20 ± 0.12 (9)	5.26 ± 0.18 (8)	5.25 ± 0.07 (10)	5.27 ± 0.08 (10)
Percent of Control			99.2	100.4	100.2	100.6
Cholesterol (mg/dL)	PND 126	120.6 ± 5.4 (10) **	121.3 ± 9.7 (9)	138.6 ± 5.5 (8)	137.1 ± 8.2 (10)	140.5 ± 4.6 (10) *
Percent of Control			100.6	114.9	113.7	116.5

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026

Time Report Requested: 11:00:33

Lab: Battelle

F1 Female: Subchronic Cohort

	Phase Day	Treatment Groups (ppm)				
		0	30	100	300	1000
Triglyceride (mg/dL)	PND 126	81.6 ± 7.2 (10)	74.1 ± 4.4 (9)	81.3 ± 5.4 (8)	78.6 ± 6.3 (10)	101.3 ± 10.2 (10)
Percent of Control			90.8	99.6	96.3	124.1
Alanine Aminotransferase (IU/L)	PND 126	42.6 ± 1.9 (10)	45.4 ± 1.8 (9)	39.5 ± 2.0 (8)	42.4 ± 1.6 (10)	42.6 ± 2.8 (9)
Percent of Control			106.7	92.7	99.5	99.9
Alkaline Phosphatase (IU/L)	PND 126	190.7 ± 12.1 (10)	182.8 ± 9.1 (9)	170.1 ± 7.5 (8)	168.6 ± 12.6 (10)	174.4 ± 9.8 (10)
Percent of Control			95.8	89.2	88.4	91.5
Aspartate Aminotransferase (U/L)	PND 126	91.70 ± 1.83 (10) *	83.11 ± 3.02 (9)	89.00 ± 3.14 (8)	88.60 ± 3.45 (10)	99.60 ± 10.85 (10)
Percent of Control			90.6	97.1	96.6	108.6
Creatine Kinase (IU/L)	PND 126	409.9 ± 49.8 (9)	320.4 ± 109.3 (9)	618.1 ± 102.4 (8)	406.9 ± 62.9 (10)	1053.0 ± 484.8 (10)
Percent of Control			78.2	150.8	99.3	256.9
Lactate Dehydrogenase (U/L)	PND 126	212.8 ± 20.7 (10)	201.3 ± 20.6 (9)	226.0 ± 25.9 (8)	225.0 ± 19.1 (10)	224.4 ± 45.2 (10)
Percent of Control			94.6	106.2	105.7	105.5
Sorbitol Dehydrogenase (IU/L)	PND 126	12.8 ± 1.4 (10)	11.2 ± 0.9 (9)	13.7 ± 0.7 (8)	12.7 ± 1.2 (10)	14.1 ± 0.8 (10)
Percent of Control			87.3	106.9	99.5	110.2
Bile salt/acids (umol/L)	PND 126	38.8 ± 7.1 (10)	36.9 ± 6.1 (9)	46.3 ± 4.3 (8)	43.1 ± 7.8 (10)	45.1 ± 7.8 (10)
Percent of Control			95.1	119.2	111.1	116.2

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026

Time Report Requested: 11:00:33

Lab: Battelle

F1 Female: Subchronic Cohort

		Treatment Groups	
	Phase Day	3000	
Urea Nitrogen (mg/dL)	PND 126	17.0 ± 0.7	(9)
Percent of Control		96.0	
Creatinine (mg/dL)	PND 126	0.54 ± 0.02	(9)
Percent of Control		104.7	
Glucose (mg/dL)	PND 126	116.8 ± 4.8	(9)
Percent of Control		105.5	
Sodium (mmol/L)	PND 126	145.7 ± 0.4	(9)
Percent of Control		100.4	
Potassium (mmol/L)	PND 126	6.1 ± 0.1	(9)
Percent of Control		96.8	
Chloride (mmol/L)	PND 126	100.3 ± 0.7	(9)
Percent of Control		100.3	
Total Protein (g/dL)	PND 126	7.47 ± 0.11	(9)
Percent of Control		102.6	
Globulin (g/dL)	PND 126	2.07 ± 0.05	(9)
Percent of Control		101.3	
A/G Ratio	PND 126	2.62 ± 0.07	(9)
Percent of Control		101.7	
Albumin (g/dL)	PND 126	5.40 ± 0.09	(9)
Percent of Control		103.1	
Cholesterol (mg/dL)	PND 126	156.3 ± 7.9	(9) **
Percent of Control		129.6	

Study Number: C11042B-01
Test Type: TOX with Perinatal Exposure
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026
Time Report Requested: 11:00:33
Lab: Battelle

F1 Female: Subchronic Cohort

		Treatment Groups	
	Phase Day	3000	
Triglyceride (mg/dL)	PND 126	86.6 ± 8.3	(9)
Percent of Control		106.1	
Alanine Aminotransferase (IU/L)	PND 126	42.3 ± 2.6	(9)
Percent of Control		99.4	
Alkaline Phosphatase (IU/L)	PND 126	166.6 ± 11.2	(9)
Percent of Control		87.3	
Aspartate Aminotransferase (U/L)	PND 126	86.33 ± 10.58	(9) *
Percent of Control		94.1	
Creatine Kinase (IU/L)	PND 126	620.0 ± 331.2	(9)
Percent of Control		151.3	
Lactate Dehydrogenase (U/L)	PND 126	211.7 ± 67.2	(9)
Percent of Control		99.5	
Sorbitol Dehydrogenase (IU/L)	PND 126	10.8 ± 1.2	(9)
Percent of Control		84.4	
Bile salt/acids (umol/L)	PND 126	44.8 ± 6.8	(9)
Percent of Control		115.4	

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026

Time Report Requested: 11:00:33

Lab: Battelle

F1 Male: Neurobehavioral Cohort

	Phase Day	Treatment Groups (ppm)				
		0	30	100	300	1000
Glucose (mg/dL)	PND 138 - 144	104.6 ± 2.5 (10)	106.4 ± 5.8 (10)	110.5 ± 7.6 (10)	113.8 ± 7.9 (10)	105.9 ± 5.6 (10)
Percent of Control			101.7	105.6	108.8	101.2
Cholesterol (mg/dL)	PND 138 - 144	121.6 ± 7.4 (10) **	117.5 ± 7.0 (10)	152.7 ± 10.6 (10) *	164.9 ± 19.1 (10) *	174.6 ± 13.8 (10) **
Percent of Control			96.6	125.6	135.6	143.6
Triglyceride (mg/dL)	PND 138 - 144	146.0 ± 13.7 (10)	135.0 ± 7.2 (10)	158.8 ± 15.6 (10)	136.8 ± 15.7 (10)	137.9 ± 16.1 (10)
Percent of Control			92.5	108.8	93.7	94.5
LDL Cholesterol (mg/dL)	PND 138 - 144	22.5 ± 1.8 (10) **	21.6 ± 1.6 (10)	30.8 ± 3.0 (10) *	33.2 ± 4.2 (10) *	35.2 ± 3.3 (10) **
Percent of Control			96.0	136.9	147.6	156.4
HDL Cholesterol (mg/dL)	PND 138 - 144	76.3 ± 4.6 (10) **	74.3 ± 5.1 (10)	97.0 ± 6.7 (10) *	107.0 ± 12.2 (10) *	113.4 ± 8.9 (10) **
Percent of Control			97.4	127.1	140.2	148.6

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026

Time Report Requested: 11:00:33

Lab: Battelle

F1 Male: Neurobehavioral Cohort

	Phase Day	Treatment Groups
		3000
Glucose (mg/dL)	PND 138 - 144	104.0 ± 2.8 (10)
Percent of Control		99.4
Cholesterol (mg/dL)	PND 138 - 144	190.0 ± 6.7 (10) **
Percent of Control		156.3
Triglyceride (mg/dL)	PND 138 - 144	113.7 ± 6.6 (10)
Percent of Control		77.9
LDL Cholesterol (mg/dL)	PND 138 - 144	37.1 ± 1.8 (10) **
Percent of Control		164.9
HDL Cholesterol (mg/dL)	PND 138 - 144	125.2 ± 5.0 (10) **
Percent of Control		164.1

Study Number: C11042B-01

Test Type: TOX with Perinatal Exposure

Route: Dosing in Feed

Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026

Time Report Requested: 11:00:33

Lab: Battelle

F1 Female: Neurobehavioral Cohort

	Phase Day	Treatment Groups (ppm)				
		0	30	100	300	1000
Glucose (mg/dL)	PND 138 - 143	103.3 ± 4.4 (10)	103.4 ± 4.1 (10)	120.0 ± 10.5 (10)	106.7 ± 4.3 (10)	105.0 ± 2.1 (10)
Percent of Control			100.1	116.2	103.3	101.6
Cholesterol (mg/dL)	PND 138 - 143	100.3 ± 7.3 (10) *	101.5 ± 4.7 (10)	110.7 ± 5.3 (10)	112.3 ± 6.2 (10)	104.8 ± 6.8 (10)
Percent of Control			101.2	110.4	112.0	104.5
Triglyceride (mg/dL)	PND 138 - 143	80.1 ± 6.8 (10)	92.1 ± 7.2 (10)	89.9 ± 6.1 (10)	76.7 ± 6.3 (10)	90.1 ± 7.6 (10)
Percent of Control			115.0	112.2	95.8	112.5
LDL Cholesterol (mg/dL)	PND 138 - 143	11.7 ± 1.0 (10)	11.6 ± 0.4 (10)	11.8 ± 0.7 (10)	14.0 ± 1.3 (10)	10.7 ± 0.9 (10)
Percent of Control			99.1	100.9	119.7	91.5
HDL Cholesterol (mg/dL)	PND 138 - 143	69.9 ± 5.6 (10) *	70.8 ± 3.6 (10)	79.4 ± 4.1 (10)	80.8 ± 4.5 (10)	73.4 ± 5.1 (10)
Percent of Control			101.3	113.6	115.6	105.0

Study Number: C11042B-01
Test Type: TOX with Perinatal Exposure
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026
Time Report Requested: 11:00:33
Lab: Battelle

F1 Female: Neurobehavioral Cohort

	Phase Day	Treatment Groups
		3000
Glucose (mg/dL)	PND 138 - 143	103.5 ± 2.4 (10)
Percent of Control		100.2
Cholesterol (mg/dL)	PND 138 - 143	123.1 ± 8.8 (10)
Percent of Control		122.7
Triglyceride (mg/dL)	PND 138 - 143	79.9 ± 5.7 (10)
Percent of Control		99.8
LDL Cholesterol (mg/dL)	PND 138 - 143	13.7 ± 1.2 (10)
Percent of Control		117.1
HDL Cholesterol (mg/dL)	PND 138 - 143	87.4 ± 6.4 (10)
Percent of Control		125.0

Study Number: C11042B-01
Test Type: TOX with Perinatal Exposure
Route: Dosing in Feed
Species/Strain: Rat/Harlan Sprague Dawley

PA41: Clinical Chemistry Summary
Test Compound: Triphenyl Phosphate (TPHP)
CAS Number: 115-86-6

Date Report Requested: 05/22/2026
Time Report Requested: 11:00:33
Lab: Battelle

LEGEND

For the F1 PND 28 Interim cohort, values are given as mean \pm SEM (N) of the litter means, with Percent of Control calculated by (dosed group mean / control group mean) x 100.

For the F1 Subchronic cohort and Neuro cohort, values are given as mean \pm SEM (N), with Percent of Control calculated by (dosed group mean / control group mean) x 100.

Statistical analysis for the F1 PND 28 Interim animals was performed using a bootstrapped Jonckheere test for trend and a Datta-Satten modified Wilcoxon test with Hommel adjustment for pairwise comparisons.

Statistical analysis for the F1 Subchronic and Neuro cohort animals was performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test.

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.

* Statistically significant at $p \leq 0.05$

** Statistically significant at $p \leq 0.01$

SEM = Standard Error of the Mean

PND = Postnatal Day

Control and some treated animals' total and direct bilirubin values were below linearity, consistent with normal baseline concentrations. The number of samples that were above linearity was low, thus no statistical analysis was conducted for these endpoints.

Clinical chemistry data not reported was removed as an outlier, or was due to pre-analytical or analytical conditions or errors including but not limited to: below linearity, short sample, quantity not sufficient, or extreme hemolysis.

**** END OF REPORT ****